Highbridge Capital Management reported beneficial ownership of 273,000 shares of Aspire Biopharma common stock issuable upon exercise of warrants, representing 5.2% of the class assuming exercise.
The filing states shares outstanding were 5,024,124 as of March 27, 2026, and the reported position reflects warrants directly held by Highbridge Funds. The statement clarifies the shares are issuable upon exercise of warrants and attributes voting and dispositive power to the Reporting Person.
Positive
None.
Negative
None.
Insights
Highbridge reports a warrant-backed stake equal to 5.2% of Aspire Biopharma on an exercised basis.
The filing lists 273,000 shares issuable upon exercise of warrants held by Highbridge Funds and calculates ownership using 5,024,124 shares outstanding as of March 27, 2026. The position is presented as beneficial ownership attributable to the Reporting Person.
Key dependencies include whether the warrants are exercised and the timing of any exercises or dispositions; cash‑flow treatment and exercise terms are not disclosed in the excerpt. Subsequent filings would show any conversion or resale activity.
Key Figures
Shares issuable upon exercise:273,000 sharesPercent of class:5.2%Shares outstanding:5,024,124 shares+2 more
5 metrics
Shares issuable upon exercise273,000 sharesissuable upon exercise of warrants held by Highbridge Funds
Percent of class5.2%assuming exercise; calculation uses shares outstanding as of March 27, 2026
Shares outstanding5,024,124 sharesas of <date>March 27, 2026</date>, per Issuer Form 10-K
CUSIP738920206Class identifier for Aspire Biopharma common stock
Filing execution date<date>May 15, 2026</date>signature date on Schedule 13G
Key Terms
issuable upon exercise of warrants, beneficially owned, Schedule 13G
3 terms
issuable upon exercise of warrantsfinancial
"Reflects shares of Common Stock issuable upon exercise of warrants."
beneficially ownedregulatory
"Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Schedule 13Gregulatory
"This statement is filed by Highbridge Capital Management, LLC"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
What stake does Highbridge hold in Aspire Biopharma (ASBP)?
Highbridge reports beneficial ownership of 273,000 shares issuable upon exercise of warrants, representing 5.2% of the class assuming exercise as stated in the filing.
How did the filing calculate the 5.2% ownership figure for ASBP?
The percentage is calculated using 5,024,124 shares outstanding as of March 27, 2026, per Aspire Biopharma's Form 10-K, and assumes exercise of Highbridge-held warrants.
Does Highbridge currently have voting or disposition power over the shares?
The filing attributes sole voting and sole dispositive power over the reported 273,000 shares to Highbridge Capital Management, as stated on the cover page incorporated by reference.
Are the reported shares already issued or only issuable upon exercise?
The filing states the shares are issuable upon exercise of warrants directly held by Highbridge Funds; they are not described as currently outstanding common shares in this excerpt.
Who filed the Schedule 13G for Aspire Biopharma?
The Schedule 13G was filed by Highbridge Capital Management, LLC, signed by Kirk Rule, Executive Director, with an execution date of May 15, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Aspire Biopharma Holdings, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
738920206
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
738920206
1
Names of Reporting Persons
Highbridge Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
273,000.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
273,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
273,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: Reflects shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aspire Biopharma Holdings, Inc.
(b)
Address of issuer's principal executive offices:
194 Candelaro Drive, #233, Humacao, Puerto Rico 00791
Item 2.
(a)
Name of person filing:
This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the common stock, par value $0.0001 per share ("Common Stock") of Aspire Biopharma Holdings Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds;
The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
(c)
Citizenship:
Highbridge is a Delaware limited liability company.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
738920206
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,024,124 shares of Common Stock outstanding as of March 27, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026, and assumes the exercise of the warrants held by Highbridge Funds.
(b)
Percent of class:
5.2%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
